Trials / Completed
CompletedNCT02364024
Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas
Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 856 (actual)
- Sponsor
- Federation Francophone de Cancerologie Digestive · Academic / Other
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm that linear quantification of CD3+ cells is a prognostic biomarker in localized colorectal carcinomas.
Detailed description
Adult patients of both gender who have underwent surgical resection of stage III colorectal carcinoma and randomised to receive a chemotherapy FOLFOX or FOLFOX + Cetuximab in the PETACC8 trial.
Conditions
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2009-05-01
- Completion
- 2017-04-01
- First posted
- 2015-02-16
- Last updated
- 2018-07-06
Source: ClinicalTrials.gov record NCT02364024. Inclusion in this directory is not an endorsement.